Guggenheim analyst Jonathan Lee downgraded Endava to Neutral from Buy without a price target. The company's fiscal Q3 results came in below management's outlook, driven by elongated deal cycles, the analyst tells investors in a research note. The firm says Endava's fiscal 2027 is shaping up as another transitional year.
